digest
Short Summary
Main recommendation: Dr. Aseem Malhotra argues that doctors should communicate statin benefits using absolute risk reduction rather than relative risk, so patients can make informed decisions. He says that for low-risk people the benefit over five years is about one in 100 for preventing a heart attack or stroke, with no proven mortality benefit in low-risk people, while high-risk patients (such as those with a prior heart attack, stent, or severe blockage) see larger gains, according to Malhotra.
Key Points
- For low-risk people with no prior heart attack, Malhotra cites roughly a 1% (1 in 100) chance over five years of a statin preventing a heart attack or stroke, with no shown prolongation of life.
- For high-risk patients (prior heart attack, stent, or severe blockage), he cites about 1 in 39 for preventing a further heart attack or non-fatal heart attack, and 1 in 83 for mortality.
- He says even industry-sponsored trial data, which dominate statin research, likely overstate the benefit.
- He notes that the WHO (2009), via Gerd Gigerenzer, called it an ethical imperative for doctors and patients to understand relative versus absolute risk, and the Medical Royal Colleges and a 2015 paper he co-authored reiterated this.
- He says the principle is poorly implemented because most doctors aren't taught it, and that wider adoption could reduce medication uptake and hit pharmaceutical industry profits.
Details Worth Noting
- Concrete instructions: Malhotra describes his own patient-conversation approach: explain the drug's benefit in absolute terms (e.g., "if you take this every day for five years, there is a one percent chance it prevents a heart attack or stroke"), state whether it extends life, then accept the patient's decision and support it. For patients who are unwilling to take the drug, he suggests discussing lifestyle changes as an alternative. No specific dosage, timing, or step-by-step protocol is given.
- The distinction he emphasizes is absolute risk reduction (the figure he says should be used) versus relative risk reduction.
- He frames the advice as a patient-autonomy issue, saying patients react differently and some will accept the risk while others prefer alternatives.
- He attributes the gap in practice partly to medical school and postgraduate education that does not teach this framing.
- These are claims from the speaker, many drawn from industry-sponsored trials he says may be exaggerated; they are not professional medical advice.
Bottom Line
Malhotra's core claim is that statin benefits for low-risk people are small in absolute terms and should be explained that way so patients can weigh them personally.
